Aldeyra Therapeutics will prioritize its ocular disease programs while placing on hold clinical development in other fields as part of a strategic prioritization program, according to a press release.
The company will focus on allergic conjunctivitis, dry eye disease and proliferative vitreoretinopathy late-stage programs to extend its cash runway through the end of 2021, the release said.
James A. Gow, MD, an ophthalmology drug development expert, has been named as senior vice president of clinical development. He previously served as vice president and global development lead for lifitegrast at Novartis, as well as in similar roles at Shire Pharmaceuticals and Takeda Pharmaceutical.
“Our renewed focus on late-stage ophthalmic programs is expected to enable considerable financial flexibility as we continue to advance novel therapies for conditions with unmet medical need,” Todd Brady, MD, PhD, president and CEO of Aldeyra, said in the release. “Consistent with our strategic prioritization of ocular disease, we are pleased to welcome Dr. Gow, an established leader in the development of ophthalmic therapeutics, as our new senior vice president of clinical development.”
Aldeyra will place on hold clinical development of topical dermal reproxalap for the treatment of ichthyosis associated with Sjögren-Larsson syndrome and ADX-1612 for the treatment of post-transplant lymphoproliferative disorder, the release said.
In addition, David J. Clark, MD, the company’s former chief medical officer, will now be in a consulting role.